<p>Journey Medical（纳斯达克代码：DERM - 获取免费报告）预计将在 2026 年 5 月 13 日星期三市场收盘后发布其 2026 年第一季度财报。分析师预计 Journey Medical 本季度每股收益为（$0.07），收入为 1547.30 万美元。有兴趣的人士可以在公司即将发布的 2026 年第一季度财报页面上找到电话会议的详细信息，最新的电话会议安排在 2026 年 5 月 13 日东部时间下午 4:30。</p>
<p>获取 <strong>Journey Medical</strong> 的提醒：</p>
<p>Journey Medical（纳斯达克代码：DERM - 获取免费报告）最近一次发布财报是在 2023 年 3 月 25 日。该公司报告本季度每股收益为（$0.04），超出分析师共识预期的（$0.06）$0.02。该公司本季度的收入为 1608 万美元，而分析师预期为 1886 万美元。Journey Medical 的净利润率为负的 18.48%，股本回报率为负的 46.40%。分析师平均预计 Journey Medical 在当前财年每股收益为$0，在下一个财年每股收益为$1。</p>
<h2>Journey Medical 股票上涨 1.2%</h2>
<p>纳斯达克 DERM 的股票在星期三开盘价为$5.18。该公司的市值为 1.4157 亿美元，市盈率为-11.02，贝塔值为 1.03。Journey Medical 的 52 周低点为$4.31，52 周高点为$9.56。该公司的债务与股本比率为 0.79，速动比率为 1.53，流动比率为 1.79。该公司的 50 日移动平均价格为$6.28，200 日移动平均价格为$7.41。</p>
<h2>机构资金流入与流出</h2>
<p>一些对冲基金和其他机构投资者最近调整了对该公司的持股。Jump Financial LLC 在第四季度将其在 Journey Medical 的持股比例提高了 46.1%。Jump Financial LLC 现在拥有 20,183 股该公司的股票，价值 156,000 美元，此前在此期间又收购了 6,373 股。美国银行（Bank of America Corp DE）在第三季度将其在 Journey Medical 的持股比例提高了 421.0%。美国银行现在拥有 21,537 股该公司的股票，价值 153,000 美元，此前在此期间又收购了 17,403 股。Marshall Wace LLP 在第四季度收购了 Journey Medical 的新头寸，价值 150,000 美元。Occudo Quantitative Strategies LP 在第四季度将其在 Journey Medical 的持股比例提高了 22.3%。Occudo Quantitative Strategies LP 现在拥有 18,913 股该公司的股票，价值 146,000 美元，此前在此期间又收购了 3,443 股。最后，富国银行（Wells Fargo &amp; Company MN）在第四季度将其在 Journey Medical 的持股比例提高了 109.1%。富国银行现在拥有 15,748 股该公司的股票，价值 121,000 美元，此前在此期间又收购了 8,215 股。机构投资者和对冲基金持有该公司 7.25% 的股票。</p>
<h2>分析师评级上调与下调</h2>
<p>一些券商最近对 DERM 发布了报告。HC Wainwright 在 2023 年 3 月 26 日的研究报告中重申了 “买入” 评级，并对 Journey Medical 的股票设定了$13.00 的目标价。Weiss Ratings 在 2023 年 4 月 20 日的研究报告中重申了 Journey Medical 的 “卖出（d-）” 评级。三位股票研究分析师对该股票给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，Journey Medical 目前的平均评级为 “持有”，平均目标价为$13.00。</p>
<p><strong>获取我们最新的 DERM 研究报告</strong></p>
<h2>Journey Medical 公司简介</h2>
<p>（获取免费报告）</p>
<p>Journey Medical Corp，总部位于新泽西州费尔菲尔德，是一家商业皮肤病学公司，专注于在美国收购、开发和营销处方皮肤病学产品。自 2019 年成立以来，该公司建立了一个包括品牌和仿制药的外用疗法组合，旨在解决多种皮肤病，包括痤疮、特应性皮炎、真菌感染和炎症性病变。</p>
<p>该公司的产品线包括抗生素/抗炎组合和基于皮质类固醇的配方，通过专有的凝胶、乳膏和泡沫载体进行递送。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们更看好的股票，胜过 Journey Medical</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9REVSTQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9REVSTQ"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在 Journey Medical 吗？</h2>
<p>在你考虑 Journey Medical 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Journey Medical 并不在名单上。</p>
<p>虽然 Journey Medical 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

DERM

标普生物技术 3 倍做多 - Direxion

标普生物技术 ETF - SPDR

<p>Journey Medical（纳斯达克代码：DERM）将于 5 月 13 日公布 2026 年第一季度财报，分析师预测每股亏损 0.07 美元，收入为 1547 万美元。该公司此前报告了 2025 年第一季度每股亏损 0.04 美元，超出预期。Journey Medical 的股票上涨了 1.2%，目前价格为 5.18 美元，市值为 1.4157 亿美元。机构投资者增加了持股，分析师的评级各不相同，平均目标价为 13.00 美元</p>

<p>Journey Medical (NASDAQ:DERM - Get Free Report) is expected to release its Q1 2026 results after the market closes on Wednesday, May 13th. Analysts expect Journey Medical to post earnings of ($0.07) per share and revenue of $15.4730 million for the quarter. Interested persons can find conference call details on the company's upcoming Q1 2026 earning report page for the latest details on the call scheduled for Wednesday, May 13, 2026 at 4:30 PM ET.</p>
<div class="lb-trans"><p>Journey Medical（纳斯达克代码：DERM - 获取免费报告）预计将在 2026 年 5 月 13 日星期三市场收盘后发布其 2026 年第一季度财报。分析师预计 Journey Medical 本季度每股收益为（$0.07），收入为 1547.30 万美元。有兴趣的人士可以在公司即将发布的 2026 年第一季度财报页面上找到电话会议的详细信息，最新的电话会议安排在 2026 年 5 月 13 日东部时间下午 4:30。</p>
</div><p>Get <strong>Journey Medical</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Journey Medical</strong> 的提醒：</p>
</div><p>Journey Medical (NASDAQ:DERM - Get Free Report) last posted its earnings results on Wednesday, March 25th. The company reported ($0.04) earnings per share for the quarter, topping analysts' consensus estimates of ($0.06) by $0.02. The firm had revenue of $16.08 million for the quarter, compared to analyst estimates of $18.86 million. Journey Medical had a negative net margin of 18.48% and a negative return on equity of 46.40%. On average, analysts expect Journey Medical to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.</p>
<div class="lb-trans"><p>Journey Medical（纳斯达克代码：DERM - 获取免费报告）最近一次发布财报是在 2023 年 3 月 25 日。该公司报告本季度每股收益为（$0.04），超出分析师共识预期的（$0.06）$0.02。该公司本季度的收入为 1608 万美元，而分析师预期为 1886 万美元。Journey Medical 的净利润率为负的 18.48%，股本回报率为负的 46.40%。分析师平均预计 Journey Medical 在当前财年每股收益为$0，在下一个财年每股收益为$1。</p>
</div><h2>Journey Medical Stock Up 1.2%</h2>
<div class="lb-trans"><h2>Journey Medical 股票上涨 1.2%</h2>
</div><p>Shares of NASDAQ DERM opened at $5.18 on Wednesday. The company has a market capitalization of $141.57 million, a P/E ratio of -11.02 and a beta of 1.03. Journey Medical has a 52-week low of $4.31 and a 52-week high of $9.56. The company has a debt-to-equity ratio of 0.79, a quick ratio of 1.53 and a current ratio of 1.79. The company's 50 day moving average price is $6.28 and its 200-day moving average price is $7.41.</p>
<div class="lb-trans"><p>纳斯达克 DERM 的股票在星期三开盘价为$5.18。该公司的市值为 1.4157 亿美元，市盈率为-11.02，贝塔值为 1.03。Journey Medical 的 52 周低点为$4.31，52 周高点为$9.56。该公司的债务与股本比率为 0.79，速动比率为 1.53，流动比率为 1.79。该公司的 50 日移动平均价格为$6.28，200 日移动平均价格为$7.41。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入与流出</h2>
</div><p>A number of hedge funds and other institutional investors have recently modified their holdings of the company. Jump Financial LLC lifted its position in shares of Journey Medical by 46.1% during the 4th quarter. Jump Financial LLC now owns 20,183 shares of the company's stock valued at $156,000 after acquiring an additional 6,373 shares during the period. Bank of America Corp DE lifted its position in shares of Journey Medical by 421.0% during the 3rd quarter. Bank of America Corp DE now owns 21,537 shares of the company's stock valued at $153,000 after acquiring an additional 17,403 shares during the period. Marshall Wace LLP acquired a new position in shares of Journey Medical during the 4th quarter valued at $150,000. Occudo Quantitative Strategies LP lifted its position in shares of Journey Medical by 22.3% during the 4th quarter. Occudo Quantitative Strategies LP now owns 18,913 shares of the company's stock valued at $146,000 after acquiring an additional 3,443 shares during the period. Finally, Wells Fargo &amp; Company MN lifted its position in shares of Journey Medical by 109.1% during the 4th quarter. Wells Fargo &amp; Company MN now owns 15,748 shares of the company's stock valued at $121,000 after acquiring an additional 8,215 shares during the period. Institutional investors and hedge funds own 7.25% of the company's stock.</p>
<div class="lb-trans"><p>一些对冲基金和其他机构投资者最近调整了对该公司的持股。Jump Financial LLC 在第四季度将其在 Journey Medical 的持股比例提高了 46.1%。Jump Financial LLC 现在拥有 20,183 股该公司的股票，价值 156,000 美元，此前在此期间又收购了 6,373 股。美国银行（Bank of America Corp DE）在第三季度将其在 Journey Medical 的持股比例提高了 421.0%。美国银行现在拥有 21,537 股该公司的股票，价值 153,000 美元，此前在此期间又收购了 17,403 股。Marshall Wace LLP 在第四季度收购了 Journey Medical 的新头寸，价值 150,000 美元。Occudo Quantitative Strategies LP 在第四季度将其在 Journey Medical 的持股比例提高了 22.3%。Occudo Quantitative Strategies LP 现在拥有 18,913 股该公司的股票，价值 146,000 美元，此前在此期间又收购了 3,443 股。最后，富国银行（Wells Fargo &amp; Company MN）在第四季度将其在 Journey Medical 的持股比例提高了 109.1%。富国银行现在拥有 15,748 股该公司的股票，价值 121,000 美元，此前在此期间又收购了 8,215 股。机构投资者和对冲基金持有该公司 7.25% 的股票。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级上调与下调</h2>
</div><p>A number of brokerages have recently issued reports on DERM. HC Wainwright restated a &#34;buy&#34; rating and issued a $13.00 price target on shares of Journey Medical in a research report on Thursday, March 26th. Weiss Ratings restated a &#34;sell (d-)&#34; rating on shares of Journey Medical in a research report on Monday, April 20th. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Journey Medical currently has an average rating of &#34;Hold&#34; and an average price target of $13.00.</p>
<div class="lb-trans"><p>一些券商最近对 DERM 发布了报告。HC Wainwright 在 2023 年 3 月 26 日的研究报告中重申了 “买入” 评级，并对 Journey Medical 的股票设定了$13.00 的目标价。Weiss Ratings 在 2023 年 4 月 20 日的研究报告中重申了 Journey Medical 的 “卖出（d-）” 评级。三位股票研究分析师对该股票给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，Journey Medical 目前的平均评级为 “持有”，平均目标价为$13.00。</p>
</div><p><strong>Get Our Latest Research Report on DERM</strong></p>
<div class="lb-trans"><p><strong>获取我们最新的 DERM 研究报告</strong></p>
</div><h2>Journey Medical Company Profile</h2>
<div class="lb-trans"><h2>Journey Medical 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Journey Medical Corp, headquartered in Fairfield, New Jersey, is a commercial dermatology company focused on acquiring, developing and marketing prescription dermatology products in the United States. Since its incorporation in 2019, the company has built a portfolio of both branded and generic topical therapies designed to address a range of skin conditions, including acne, atopic dermatitis, fungal infections and inflammatory lesions.</p>
<div class="lb-trans"><p>Journey Medical Corp，总部位于新泽西州费尔菲尔德，是一家商业皮肤病学公司，专注于在美国收购、开发和营销处方皮肤病学产品。自 2019 年成立以来，该公司建立了一个包括品牌和仿制药的外用疗法组合，旨在解决多种皮肤病，包括痤疮、特应性皮炎、真菌感染和炎症性病变。</p>
</div><p>The company's product lineup features antibiotic/anti-inflammatory combinations and corticosteroid-based formulations delivered through proprietary gel, cream and foam vehicles.</p>
<div class="lb-trans"><p>该公司的产品线包括抗生素/抗炎组合和基于皮质类固醇的配方，通过专有的凝胶、乳膏和泡沫载体进行递送。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Journey Medical</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Journey Medical</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9REVSTQ" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=DERM"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Journey Medical Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 Journey Medical 吗？</h2>
</div><p>Before you consider Journey Medical, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Journey Medical 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Journey Medical wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Journey Medical 并不在名单上。</p>
</div><p>While Journey Medical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Journey Medical 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Journey Medical (DERM) 预计将在周三公布财报